Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer

PURPOSE: Antiproliferative and antiosteoclastic activity from preclinical models show potential for dasatinib, an oral SRC and SRC family kinase inhibitor, as a targeted therapy for patients with prostate cancer. This phase II study investigated the activity of dasatinib in patients with metastatic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yu, Evan Y., Wilding, George, Posadas, Edwin, Gross, Mitchell, Culine, Stephane, Massard, Christophe, Morris, Michael J., Hudes, Gary, Calabrò, Fabio, Cheng, Shinta, Trudel, Géralyn C., Paliwal, Prashni, Sternberg, Cora N.
Formato: Artigo
Idioma:Inglês
Publicado em: 2009
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3394097/
https://ncbi.nlm.nih.gov/pubmed/19920114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-1691
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados